biotech · Unresectable or metastatic conventional chondrosarcoma · Advanced or metastatic solid tumors · INBX
Inhibrx Biosciences
Inhibrx Biosciences is a biotech organization headquartered in San Diego, USA. It trades on NYSE under ticker INBX. Primary therapeutic focus areas include Unresectable or metastatic conventional chondrosarcoma, Advanced
San Diego, USA HQ
2010 Founded
114 Employees
Public company Type
INBX · NYSE Ticker
Company details
- Status
- Public
- HQ
- San Diego, USA
- Founded
- 2010
- Employees
- 114
- Programs
- 10
- Drugs
- 17
- Patents
- 35
INBRX-106
Phase 3 · small molecule · Head and Neck Squamous Cell Carcinoma (HNSCC)
INBRX-106 for Head and Neck Squamous Cell Carcinoma (HNSCC) is a Phase 3 program (small_molecule) at Inhibrx Biosciences with 1 ClinicalTrials.gov record(s).
Internal code INBRX106-01-201
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Inhibrx Biosciences
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Head and Neck Squamous Cell Carcinoma (HNSCC)
- Status
- active
- Trials
- 1